Leading Microbiome Platform AMILI's position as Southeast Asia's top precision gut microbiome company and its exclusive gut microbiome transplant bank highlight its leadership and potential for expanding partnerships with healthcare providers interested in advanced microbiome therapies.

Strategic Funding Recent Series A financing of 10.5 million USD and new investments from East Ventures signal strong investor confidence, providing opportunities to leverage these connections for strategic collaborations within the health and biotech sectors.

Partner Network Growth Partnership with organizations like Cordlife indicates an interest in expanding microbiome banking and related services, opening doors for sales of microbiome testing, banking solutions, and related biotech products.

Healthcare Innovation Focus AMILI’s emphasis on integrating microbiome science into healthcare suggests potential sales of clinical testing services, health diagnostics, and personalized medicine solutions to hospitals, clinics, and health professionals.

Technology & Data Assets With an extensive Asian microbiome database and advanced platform insights, there are opportunities to offer data-driven health solutions, research collaborations, and technology licensing to pharmaceutical and research organizations.